Ina Nepstad
Bergen, 5021, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Journal: International journal of molecular sciences
Published: January 31, 2020
Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.
Journal: Signal transduction and targeted therapy
Published: November 12, 2018
Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis.
Journal: Cancers
Published: July 24, 2018
Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
Journal: Expert opinion on therapeutic targets
Published: June 12, 2018
Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.
Journal: Frontiers in medicine
Published: February 02, 2018
Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
Journal: International journal of molecular sciences
Published: December 06, 2017
Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.
Journal: Expert opinion on therapeutic targets
Published: March 11, 2017
Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells.
Journal: Oncotarget
Published: February 09, 2017
Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Journal: Expert opinion on investigational drugs
Published: December 22, 2016
Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.
Journal: Frontiers in immunology
Published: May 31, 2016
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.
Journal: Cell reports
Published: December 26, 2014
STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.
Journal: Expert review of hematology
Published: November 07, 2014
Last Updated: 09/26/2026